Eli Lilly's antibody combination reduces risk of death from Covid-19 - study
The results are from over 1,000 participants of the study, which is testing the combination of bamlanivimab and etesevimab
FILE PHOTO: The logo and ticker for Eli Lilly and Co. are displayed on a screen on the floor of the New York Stock Exchange (NYSE) in New York, US, May 18, 2018. REUTERS/Brendan McDermid
Eli Lilly and Co said on Tuesday treatment with a combination of two of its antibodies helped reduce risk of hospitalizations and death due to Covid-19 by 70%, according to results from a late-stage trial.
The results are from over 1,000 participants of the study, which is testing the combination of bamlanivimab and etesevimab.
Keep updated, follow The Business Standard's Google news channel
